J.P. Morgan 2026: Signals of Renewed Interest in Sleep MedicineByNicholas Jacobus,Graham GoodrichJanuary 14th 2026Graham Goodrich, CCO, Apnimed, outlines how advances in diagnostics, growing recognition of sleep apnea’s systemic impact, and emerging oral therapies are driving renewed momentum in sleep medicine as Apnimed advances toward commercialization.